Inthera Bioscience AG expands management team

26 June 2018 | News

Inthera Bioscience AG Expands Management Team with Seasoned Professionals and Secures €4.7 Million Second Tranche of €9.6 Million Series A Financing

Inthera Bioscience AG, a pre-clinical stage oncology company targeting the inhibition of protein-protein interactions with innovative small molecule chemistry, today announced that three senior Pharma and Biotech Industry members joined its management team.

Bernd Hentsch joins the company as Chief Development Officer, Ralph Lindemann as Chief Scientific Officer and Monique Schiersing as Chief Operating Officer.

The company is also pleased to announce that it secured the second tranche of its Series A financing, bringing the total amount to €9.6 million.

Bernd Hentsch, Ph.D. has held various senior positions in the European Biotech industry. Prior to joining Inthera Bioscience

he was Chief Development Officer at 4SC AG, a German clinical stage oncology company and TopoTarget A/S, a Danish clinical stage oncology company.

Prior to TopoTarget A/S, Bernd has held other R&D related positions, e.g. in Germany at Merck KGaA, Darmstadt, the German Cancer Research Center, Heidelberg, and at the Walter and Eliza Hall Institute in Melbourne, Australia.

Ralph Lindemann, Ph.D. joins Inthera Bioscience from Merck KGaA, Darmstadt, Translational Innovation Platform Oncology. He has 15 years of experience in translational research and drug discovery and an academic track record in chromatin-based therapeutics.

Monique Schiersing, M.Sc., MBA served previously as Investment Director at the Roche Venture Fund, F. Hoffmann–La Roche AG's corporate venture fund. In this role Monique served as Director on the board of various Biotech companies in the US as well as in Europe, amongst others Macrolide Pharmaceuticals, Inc., Minoryx Therapeutics S.L., or mySugr GmbH. Prior to this role, Monique held positions as Principal at BankInvest in Copenhagen and Global Alliance Director at Roche Pharma Partnering in Basel.